Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 95

Sort by

Sort Order Select

Journal Articles

Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematologic Malignancies. Results from a Phase I/II Trial

Blood (2023) 142 (Supplement 1): 5907.

https://doi.org/10.1182/blood-2023-179168

Published: 2023

Journal Articles

Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II Trial

Shukaib Arslan, Shaun Fleming, Nitin Jain, Giovanni Martinelli, Anthony S. Stein, James S. Blachly, Ashish Bajel, Antonio Curti, Giovanni Marconi, Giulia Fabbri, Yotvat Marmor, Shringi Sharma, Nairouz Elgeioushi, Natalia Couto-Francisco, Jamal Saeh, Raoul Tibes, Fathima Zumla Cader, Marina Konopleva

Blood (2022) 140 (Supplement 1): 9091–9093.

https://doi.org/10.1182/blood-2022-166192

Published: 2022

Journal Articles

NIMBLE: A Phase I/II Study of AZD0466 Monotherapy or in Combination in Patients with Advanced Hematological Malignancies

Marina Konopleva, Nitin Jain, Courtney L Andersen, Natalia Couto Francisco, Nairouz Elgeioushi, Rosalind Hobson, Martin Scott, John Stone, Shringi Sharma, Pablo Morentin Gutierrez, Raoul Tibes, Barry Davies, Thomas Winkler, Giulia Fabbri, Fathima Zumla Cader, Nicole McNeer

Blood (2021) 138 (Supplement 1): 2353.

https://doi.org/10.1182/blood-2021-147482

Published: 2021

Journal Articles

Real-World Use of Enasidenib in Relapsed or Refractory Acute Myeloid Leukemia Is Associated with Reduced Risk of Disease Progression and Death

Andrew J Klink, PhD MPH, Ronda Copher, PhD, Russell L. Knoth, Landon Marshall, PharmD, PhD, Ying Hou, MD, Ajeet Gajra, MD MBBS, Raoul Tibes, MD PhD

Blood (2020) 136 (Supplement 1): 18.

https://doi.org/10.1182/blood-2020-140005

Published: 2020

Journal Articles

Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration

Michael R. Savona, MD, Hagop M. Kantarjian, MD, Gail J. Roboz, MD, Casey L. O'Connell, MD, Katherine J. Walsh, MD, Raoul Tibes, MD PhD, Karen W.L. Yee, MD, Wendy Stock, MD, Elizabeth A. Griffiths, MD, Elias Jabbour, MD, Scott D. Lunin, MD, Todd L. Rosenblat, MD MS, Nikolai A. Podoltsev, MD PhD, Jean-Pierre Issa, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 2957.

https://doi.org/10.1182/blood-2019-129962

Published: 2019

Journal Articles

Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response

Karen W.L. Yee, MD, Gail J. Roboz, MD, Casey L. O'Connell, MD, Elizabeth A. Griffiths, MD, Raoul Tibes, MD PhD, Katherine J. Walsh, MD, Wendy Stock, MD, Guillermo Garcia-Manero, MD, Michael R. Savona, MD, Farhad Ravandi, MD, Naval G. Daver, MD, Elias Jabbour, MD, Todd L. Rosenblat, MD MS, Jean-Pierre Issa, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Hagop M. Kantarjian, MD

Blood (2019) 134 (Supplement_1): 3846.

https://doi.org/10.1182/blood-2019-129845

Published: 2019

Journal Articles

DNA Damage Repair Interference By WEE1 Inhibition with AZD1775 Overcomes Combined Azacitidine and Venetoclax Resistance in Acute Myeloid Leukmeia (AML)

Raoul Tibes, MD PhD, Diego Ferreira Coutinho, PhD, Michael Tuen Tuen, Xufeng Chen, PhD, Christina Glytsou, Ioannis Aifantis, Sergey Shmelkov, MD

Blood (2019) 134 (Supplement_1): 2559.

https://doi.org/10.1182/blood-2019-130931

Published: 2019

Journal Articles

RAC1 Inhibitor EHT1864 and Venetoclax Overcome Midostaurin Resistance in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 1277.

https://doi.org/10.1182/blood-2019-129762

Published: 2019

Journal Articles

Midostaurin in Combination with Idarubicin and Cytarabine (3+7) Induction for FLT3 Positive AML - Very High Complete Response Rates and Transition to Allogeneic Transplantation

Jacques Azzi, MD, Frank Cirrone, PharmD, Maher Abdul Hay, MD, David Kaminetzky, MD, Kenneth B. Hymes, MD, Maxim Kreditor, MD, Ahmad-Samer Al-Homsi, MD, Michael L. Grossbard, MD, Catherine Diefenbach, MD, Tibor Moskovits, MD, Shella Saint Fleur-Lominy, MD PhD, Bruce G. Raphael, MD, Raoul Tibes, MD PhD

Blood (2018) 132 (Supplement 1): 5216.

https://doi.org/10.1182/blood-2018-99-117314

Published: 2018

Journal Articles

The HACE1-NRF2 Axis a Novel Target in Acute Myeloid Leukemia

Andoni Garitano-Trojaola, PhD, Eva Teufel, Nadine Rodhes, Jennifer Kreckel, Thorsten Stuehmer, Matteo Claudio Da Via', MD, Santiago Barrio Garcia, PhD, Torsten Haferlach, MD, Raoul Tibes, Harald Wajant, Andreas Rosenwald, Hermann Einsele, MD, K. Martin Kortüm, MD

Blood (2018) 132 (Supplement 1): 5132.

https://doi.org/10.1182/blood-2018-99-118270

Published: 2018

Journal Articles

The Role of NRAS G12D Mutations in the Response to Conventional Chemotherapy and 5-Azacitidine in Secondary AML

Andoni Garitano-Trojaola, PhD, Eva Teufel, Matteo Claudio Da Via', MD, Ana Sancho, Nadine Rodhes, Thorsten Stuehmer, Santiago Barrio Garcia, PhD, Jürgen Groll, Torsten Haferlach, MD, Raoul Tibes, Andreas Rosenwald, Hermann Einsele, MD, Martin Kortüm, MD

Blood (2018) 132 (Supplement 1): 5148.

https://doi.org/10.1182/blood-2018-99-118484

Published: 2018

Journal Articles

Therapeutic Targeting of an RNA Splicing Factor Network for the Treatment of Myeloid Neoplasms

Sydney X. Lu, MD PhD, Eric Wang, Alessandro Pastore, Chen Xufeng, PhD, Jochen Imig, PhD, Stanley C Lee, PhD, Yohana Ghebrechristos, Akihide Yoshimi, MD, Lillian E Bitner, BSc, Michelle Ki, BSc, Andreas Kloetgen, Kuan-Ting Lin, PhD, Raoul Tibes, MD PhD, Adrian R. Krainer, PhD, Taisuke Uehara, Takashi Owa, PhD, Iannis Aifantis, PhD, Omar I Abdel-Wahab, MD

Blood (2018) 132 (Supplement 1): 427.

https://doi.org/10.1182/blood-2018-99-111430

Published: 2018

Journal Articles

A Phase II of Combination Daunorubicin and Cytarabine (Ara-C) and Nilotinib (TASIGNA) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Final Results

Aref Al-Kali, MD, Raoul Tibes, MD PhD, Jeanne Palmer, MD, Hassan B. Alkhateeb, MD, Mrinal M. Patnaik, MD MBBS, Kebede H. Begna, MD, Naseema Gangat, MBBS, Pamela Atherton, Shujun Liu, PhD, Rong He, MD, Shahrukh K. Hashmi, MD MPH, Mark R. Litzow, MD

Blood (2018) 132 (Supplement 1): 1443.

https://doi.org/10.1182/blood-2018-99-118552

Published: 2018

Journal Articles

Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Blood (2018) 132 (Supplement 1): 231.

https://doi.org/10.1182/blood-2018-99-110465

Published: 2018

Journal Articles

Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations

Mark J. Levis, MD, Alexander E. Perl, MD, Jessica K. Altman, MD, Jorge E. Cortes, MD, Catherine C. Smith, MD, Maria R. Baer, MD, David F. Claxton, MD, Joseph G. Jurcic, MD, Ellen K. Ritchie, MD, Stephen A. Strickland, MD, Raoul Tibes, MD PhD, Jason E. Hill, PhD, Matt Rosales, Erkut Bahceci, MD

Blood (2018) 132 (Supplement 1): 1458.

https://doi.org/10.1182/blood-2018-99-110971

Published: 2018

Journal Articles

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

Blood (2018) 131 (24): 2661–2669.

https://doi.org/10.1182/blood-2017-12-818948

Published: 2018

Includes: Supplemental data

Journal Articles

A Two-Part Study of Givinostat in Patients with Polycythemia Vera: The Maximum Tolerated Dose Selection and the Proof of Concept Final Results

Blood (2017) 130 (Supplement 1): 253.

https://doi.org/10.1182/blood.V130.Suppl_1.253.253

Published: 2017

Journal Articles

Evaluation of the Impact of Minimal Residual Disease, FLT3 Allelic Ratio, and FLT3 Mutation Status on Overall Survival in FLT3 Mutation-Positive Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the Chrysalis Phase 1/2 Study

Mark J. Levis, MD, Alexander E. Perl, MD, Jessica K. Altman, MD, Jorge E. Cortes, MD, Catherine C. Smith, MD, Maria R. Baer, MD, David F. Claxton, Joseph G. Jurcic, MD, Ellen K Ritchie, MD, Stephen A Strickland, Raoul Tibes, Jason Hill, PhD, Shufang Liu, Erkut Bahceci, MD

Blood (2017) 130 (Supplement 1): 2705.

https://doi.org/10.1182/blood.V130.Suppl_1.2705.2705

Published: 2017

Journal Articles

Genomic Analysis of Hairy Cell Leukemia Identifies Novel Recurrent Genetic Alterations

Blood (2017) 130 (Supplement 1): 2994.

https://doi.org/10.1182/blood.V130.Suppl_1.2994.2994

Published: 2017

Journal Articles

A Single Center Analysis of Clofarabine Use Prior to Bone Marrow Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Caleb J Scheckel, DO, Jeffrey Alan Betcher, BSPharm, RPh, Lisa Sproat, MD MSW, Nandita Khera, MD, James L. Slack, MD, Jose F. Leis, MD PhD, Pierre Noel, MD, Raoul Tibes, Lanyu Mi, MS, Jeanne Palmer, MD

Blood (2017) 130 (Supplement 1): 5057.

https://doi.org/10.1182/blood.V130.Suppl_1.5057.5057

Published: 2017

NARROW

Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematologic Malignancies. Results from a Phase I/II Trial

Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II Trial

NIMBLE: A Phase I/II Study of AZD0466 Monotherapy or in Combination in Patients with Advanced Hematological Malignancies

Real-World Use of Enasidenib in Relapsed or Refractory Acute Myeloid Leukemia Is Associated with Reduced Risk of Disease Progression and Death

Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration

Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response

DNA Damage Repair Interference By WEE1 Inhibition with AZD1775 Overcomes Combined Azacitidine and Venetoclax Resistance in Acute Myeloid Leukmeia (AML)

RAC1 Inhibitor EHT1864 and Venetoclax Overcome Midostaurin Resistance in Acute Myeloid Leukemia

Midostaurin in Combination with Idarubicin and Cytarabine (3+7) Induction for FLT3 Positive AML - Very High Complete Response Rates and Transition to Allogeneic Transplantation

The HACE1-NRF2 Axis a Novel Target in Acute Myeloid Leukemia

The Role of NRAS G12D Mutations in the Response to Conventional Chemotherapy and 5-Azacitidine in Secondary AML

Therapeutic Targeting of an RNA Splicing Factor Network for the Treatment of Myeloid Neoplasms

A Phase II of Combination Daunorubicin and Cytarabine (Ara-C) and Nilotinib (TASIGNA) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Final Results

Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

A Two-Part Study of Givinostat in Patients with Polycythemia Vera: The Maximum Tolerated Dose Selection and the Proof of Concept Final Results

Evaluation of the Impact of Minimal Residual Disease, FLT3 Allelic Ratio, and FLT3 Mutation Status on Overall Survival in FLT3 Mutation-Positive Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the Chrysalis Phase 1/2 Study

Genomic Analysis of Hairy Cell Leukemia Identifies Novel Recurrent Genetic Alterations

A Single Center Analysis of Clofarabine Use Prior to Bone Marrow Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only